Pharmacokinetic Considerations in the Treatment of Methicillin-resistant Staphylococcus aureus Osteomyelitis

摘要

In the United States, >2 million Americans become infected with a hospital-acquired organism each year. Over 70% of these infections are caused by a bacteria resistant to at least one agent typically used in treatment. Unfortunately, approximately 90,000 of these patients will die. The emergence of multidrug-resistant organisms complicates the treatment of osteomyelitis, an already difficult-to-treat infection.Staphylococcus aureus is one of the most common bacteria isolated in osteomyelitis cases, and treatment can be difficult because of resistant strains that have emerged.Data from 2003 indicate that resistance rates for methicillin-resistant S aureus are approaching 60% in United States intensive care units, a 12% increase from 1998-2002 results.